Search

everythinglearnresearchcommunity

for

Search:↓

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

Stopping gefitinib improved scalp condition in a woman with lung cancer.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

M30 is a promising treatment for preventing hair loss during chemotherapy.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Erlotinib can cause hair loss and texture changes.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

Oral contraceptive use may increase the risk of frontal fibrosing alopecia in women with a specific CYP1B1 gene variant.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

RNA aptamers can specifically block FGF5-related cell growth, potentially treating related diseases or hair disorders.

Radiation treatment causes skin fibrosis by increasing certain fibroblast subpopulations, but using a c-Jun inhibitor or fat grafting can reduce this effect.

Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.

A man with kidney tumors and lung cysts was diagnosed with Birt–Hogg–Dubé syndrome and treated successfully, with genetic testing confirming the diagnosis.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Vorasidenib can cause unusual hair growth.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

Researchers found certain genes are overactive and others are underactive in men with early balding, which could help create new treatments.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Researchers found potential new targets for treating melanoma and nonmelanoma skin cancers, and identified a possible cause and treatment for male pattern baldness and eczema.

Blocking mTORC1 may help prevent skin cancer by stopping the growth of certain skin stem cells.

Ruxolitinib helped a patient with alopecia areata regrow hair.